United Therapeutics FY2021 revenue $1.69B (+14% YoY); Tyvaso DPI decision pushed to May 2022

UNITED THERAPEUTICS Corp

2021-FY EPS reported $10.06 revenue$1,685,500,000

Full year 2021 revenue $1.69B, up 14% YoY; Q4 revenue $415M, up 8% YoY.
Net income $475.8M ($10.60 basic GAAP EPS); non-GAAP diluted EPS $15.26.
Tyvaso net sales $607.5M in 2021, up 26% YoY; Remodulin down 1% to $513.7M.
Tyvaso DPI NDA extended to May 2022 after FDA requested info on pulmonary safety related to Citizen Petition.
Patient count reached all-time high; target of 6,000 Tyvaso patients by end of 2022 reaffirmed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.